Tokyo - Delayed Quote JPY

CellSeed Inc. (7776.T)

546.00
0.00
(0.00%)
At close: 3:30:00 PM GMT+9
Loading Chart for 7776.T
  • Previous Close 546.00
  • Open 544.00
  • Bid 546.00 x --
  • Ask 547.00 x --
  • Day's Range 536.00 - 564.00
  • 52 Week Range 211.00 - 1,160.00
  • Volume 1,257,200
  • Avg. Volume 2,065,587
  • Market Cap (intraday) 18.928B
  • Beta (5Y Monthly) 0.87
  • PE Ratio (TTM) --
  • EPS (TTM) -25.72
  • Earnings Date Aug 12, 2025 - Aug 18, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

www.cellseed.com

44

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 7776.T

View More

Performance Overview: 7776.T

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

7776.T
36.84%
Nikkei 225 (^N225)
7.29%

1-Year Return

7776.T
149.32%
Nikkei 225 (^N225)
4.22%

3-Year Return

7776.T
287.23%
Nikkei 225 (^N225)
38.32%

5-Year Return

7776.T
42.19%
Nikkei 225 (^N225)
81.41%

Compare To: 7776.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7776.T

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    18.93B

  • Enterprise Value

    16.94B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    97.93

  • Price/Book (mrq)

    8.75

  • Enterprise Value/Revenue

    87.63

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.81%

  • Return on Equity (ttm)

    -71.66%

  • Revenue (ttm)

    161M

  • Net Income Avi to Common (ttm)

    -914M

  • Diluted EPS (ttm)

    -25.72

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    930M

  • Total Debt/Equity (mrq)

    15.50%

  • Levered Free Cash Flow (ttm)

    -580.63M

Research Analysis: 7776.T

View More

Company Insights: 7776.T

Research Reports: 7776.T

View More

People Also Watch